That insightful analyst (R Hemming) is back with another article today
http://www.businessday.com.au/business/volatile-royalties-often-bitter-pills-for-biotechs-20120429-1xsyk.html
Why he ties PRR to these other royalty based biotechs is a mystery and only confirms his overall personal agenda.
PRR is not the sole focus of the article but here is excerpt:
"This column had the temerity to suggest that Prima's market cap of $256 million might be overdoing it for a company that hasn't got much in the way of clinical evidence and even if everything goes to plan, will not make a profit for at least another four years."
That insightful analyst (R Hemming) is back with another article...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $537.4M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.3¢ | 36.5¢ | $1.060M | 2.841M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 48648 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 13814 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |